Port delivery system with ranibizumab in the treatment of diabetic retinopathy without center-involved diabetic macular edema: primary analysis results of the phase 3 Pavilion trial

被引：0
|
作者：
Emanuelli, Andres [1 ,2 ]
Holekamp, Nancy [3 ]
Latkany, Paul [4 ]
Brittain, Christopher [4 ]
Howard, Dena [5 ]
Santhanakrishnan, Anjana [4 ]
Wetzel-Smith, Monica [4 ]
Quezada-Ruiz, Carlos [4 ]
Malhotra, Varun [4 ]
Pieramici, Dante [6 ]
机构：
[1] Emanuelli Res & Dev, Arecibo, PR USA
[2] Univ Puerto Rico, Sch Med, Dept Ophthalmol, San Juan, PR USA
[3] Pepose Vis Inst, Chesterfield, MO USA
[4] Genentech Inc, San Francisco, CA USA
[5] Roche Prod Ltd, Welwyn Garden City, Herts, England
[6] Calif Retina Consultants, Santa Barbara, CA USA
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2023年 / 64卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Port Delivery System With Ranibizumab vs Monitoring in Nonproliferative Diabetic Retinopathy Without Macular Edema: The Pavilion Randomized Clinical Trial
    Pieramici, Dante J.
    Awh, Carl C.
    Chang, Margaret
    Emanuelli, Andres
    Holekamp, Nancy M.
    Hu, Allen Y.
    Suner, Ivan J.
    Wykoff, Charles C.
    Brittain, Christopher
    Howard, Dena
    Quezada-Ruiz, Carlos
    Santhanakrishnan, Anjana
    Latkany, Paul
    JAMA OPHTHALMOLOGY, 2025,
  • [2] PHASE 3 TRIALS OF PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC RETINOPATHY (DR) WITH OR WITHOUT DIABETIC MACULAR EDEMA (DME)
    Cooper, B.
    Chang, M.
    Smith, R.
    Malhotra, V.
    Latkany, P.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2022, 24 : A185 - A185
  • [3] Port Delivery System with Ranibizumab (PDS) in Diabetic Retinopathy (DR) with or without Diabetic Macular Edema (DME)
    Chang, Margaret
    Bobbala, Ashwini
    Malhotra, Varun
    Latkany, Paul
    DIABETES, 2021, 70
  • [4] Port Delivery System With Ranibizumab (PDS) in diabetic macular edema (DME): additional primary analysis results of the phase 3 Pagoda trial
    Malhotra, Varun
    Klufas, Michael A.
    Marcus, Dennis M.
    Graff, Jordan M.
    Campochiaro, Peter A.
    Rahman, Salman
    Latkany, Paul
    Gune, Shamika
    DeGraaf, Stephanie
    Bobbala, Ashwini
    Rabena, Mel
    Ruiz, Carlos
    Khanani, Arshad M.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (07)
  • [5] Port Delivery System with ranibizumab (PDS) stabilizes retinal nonperfusion and macular leakage: results from Pagoda and Pavilion phase 3 trials in diabetic macular edema (DME) and diabetic retinopathy (DR)
    Wirthlin, Robert
    Gill, Manjot
    Howard, Dena
    Menezes, Alicia
    Rahman, Salman
    Latkany, Paul
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (07)
  • [6] Pharmacodynamics of Ranibizumab treatment of center-involved diabetic macular oedema
    Hodzic-Hadzibegovic, Delila
    Sander, Birgit Agnes
    Lund-Andersen, Henrik
    Larsen, Michael
    ACTA OPHTHALMOLOGICA, 2014, 92 : 18 - 19
  • [7] Rationale for the Diabetic Retinopathy Clinical Research Network Treatment Protocol for Center-Involved Diabetic Macular Edema
    Aiello, Lloyd Paul
    Beck, Roy W.
    Bressler, Neil M.
    Browning, David J.
    Chalam, K. V.
    Davis, Matthew
    Ferris, Frederick L., III
    Glassman, Adam R.
    Maturi, Raj K.
    Stockdale, Cynthia R.
    Topping, Trexler M.
    OPHTHALMOLOGY, 2011, 118 (12) : E5 - E14
  • [8] Exploratory Analysis of Persistent Macular Thickening Following Intravitreal Ranibizumab for Center-Involved Diabetic Macular Edema
    Maturi, Raj
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [9] Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular Edema The Pagoda Randomized Clinical Trial
    Khanani, Arshad M.
    Campochiaro, Peter A.
    Graff, Jordan M.
    Marcus, Dennis M.
    Miller, Daniel
    Mittra, Robert A.
    Regillo, Carl
    Sheth, Veeral S.
    Bobbala, Ashwini
    Gune, Shamika
    Lin, Stephanie
    Quezada-Ruiz, Carlos
    Malhotra, Varun
    JAMA OPHTHALMOLOGY, 2025,
  • [10] Port Delivery System with ranibizumab (PDS) met primary endpoint and key secondary outcomes with > 75% of patients preferring PDS treatment in phase 3 Pavilion trial for diabetic retinopathy (DR)
    Latkany, Paul
    Regillo, Carl
    Wykoff, Charles C.
    Chang, Margaret
    Emanuelli, Andres
    Holekamp, Nancy
    Malhotra, Varun
    Howard, Dena
    Santhanakrishnan, Anjana
    Wetzel-Smith, Monica
    Quezada-Ruiz, Carlos
    Pieramici, Dante Joseph
    Latkany, Paul
    Regillo, Carl
    Wykoff, Charles C.
    Chang, Margaret
    Emanuelli, Andres
    Holekamp, Nancy
    Malhotra, Varun
    Howard, Dena
    Santhanakrishnan, Anjana
    Wetzel-Smith, Monica
    Quezada-Ruiz, Carlos
    Pieramici, Dante Joseph
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (07)
12345